NASDAQ · NVAX
Healthcare · Biotechnology
$9.23
Down-$0.36 (-3.75%)
Updated Sep 16, 2026, 11:14 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NVAX closed at $9.23 after 20 trading sessions, up 16.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $9.50 | $9.56 | $9.16 | $9.23 | 3.33M |
| Sep 14, 2026 | $9.38 | $9.60 | $9.135 | $9.59 | 3.37M |
| Sep 11, 2026 | $9.29 | $9.865 | $9.23 | $9.42 | 6.12M |
| Sep 10, 2026 | $9.64 | $9.68 | $9.11 | $9.30 | 5.89M |
| Sep 9, 2026 | $10.02 | $10.242 | $9.73 | $9.85 | 4.44M |
| Sep 8, 2026 | $10.099 | $10.3599 | $9.75 | $10.19 | 4.23M |
| Sep 4, 2026 | $10.50 | $10.7496 | $10.045 | $10.22 | 5.13M |
| Sep 3, 2026 | $10.415 | $10.48 | $9.9001 | $10.34 | 6.23M |
| Sep 2, 2026 | $10.275 | $10.73 | $9.96 | $10.32 | 5.64M |
| Sep 1, 2026 | $9.20 | $10.261 | $9.19 | $10.12 | 10.04M |
| Aug 31, 2026 | $9.10 | $9.985 | $9.09 | $9.37 | 7.27M |
| Aug 28, 2026 | $9.18 | $9.34 | $8.89 | $9.26 | 4.21M |
| Aug 27, 2026 | $9.12 | $9.18 | $8.915 | $9.05 | 3.43M |
| Aug 26, 2026 | $9.33 | $9.44 | $9.13 | $9.21 | 3.51M |
| Aug 25, 2026 | $9.07 | $9.58 | $8.93 | $9.44 | 7.11M |
| Aug 24, 2026 | $8.87 | $8.98 | $8.26 | $8.86 | 5.58M |
| Aug 21, 2026 | $8.44 | $9.1995 | $8.435 | $8.94 | 10.45M |
| Aug 20, 2026 | $8.50 | $8.66 | $8.02 | $8.42 | 5.98M |
| Aug 19, 2026 | $8.43 | $8.83 | $8.19 | $8.79 | 11.45M |
| Aug 18, 2026 | $7.97 | $8.08 | $7.835 | $7.93 | 2.02M |
The latest Smart Investors Daily articles mentioning NVAX.
NVAX research
Company profile and research snapshot.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 11, 2026 | BTIG | Buy | — |
| May 6, 2026 | TD Cowen | Hold | — |
| Feb 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 20, 2026 | BTIG | Buy | — |
| Nov 18, 2025 | JP Morgan | Underweight | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.
Yahoo · Sep 15, 2026
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
Yahoo · Sep 15, 2026
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Yahoo · Sep 12, 2026
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVAX.
